Gyre Therapeutics, INC Form 4 insider transactions

Ma Songjiang, President and Director of GYRE Therapeutics, Inc., has reported the sale of 2,558 shares of common stock in late May 2025, executed under a pre-established Rule 10b5-1 trading plan.

GYRE Therapeutics, Inc. Director and 10% Owner Ping Zhang was granted 250,000 stock options with an exercise price of $10.18, vesting over four years.

GYRE Therapeutics' President and Director, Songjiang Ma, sold a total of 2,182 shares of common stock in May 2025, executed under a pre-established Rule 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on May 20 and 21, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on May 14 and 15, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Weiguo Ye, Chief Operating Officer of Gyre Therapeutics, exercised stock options and disposed of 50,000 common stock shares on April 1, 2025.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on May 12 and 13, 2025, under a pre-arranged 10b5-1 trading plan.

Weiguo Ye, Chief Operating Officer of Gyre Therapeutics, exercised stock options to acquire a total of 650,000 shares of common stock between March 24 and March 27, 2025.

Thomas Wilson Eastling, a director at Gyre Therapeutics, exercised stock options to acquire 15,000 shares of common stock at $6.93 per share on April 16, 2025.

Songjiang Ma, President of Gyre Therapeutics, sold 174 shares of common stock at $10.00 per share under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on March 19 and 20, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on March 17 and 18, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on March 13 and 14, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on March 11 and 12, 2025, under a pre-arranged 10b5-1 trading plan.

Weiguo Ye, Chief Operating Officer of Gyre Therapeutics, was granted options to purchase 300,000 shares of common stock.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock between March 7 and March 10, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock over two days under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on March 3rd and 4th, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 27 and 28, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 25th and 26th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock between February 21 and February 24, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock on February 19th and 20th, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock in two transactions executed under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 12 and 13, 2025, under a pre-arranged trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 10th and 11th, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 6th and 7th, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 4th and 5th, 2025, under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 31, 2025 and February 3, 2025 under a pre-arranged 10b5-1 trading plan.

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 29th and 30th, 2025, under a pre-arranged 10b5-1 trading plan.